Press "Enter" to skip to content

Eisai enters into licensing agreement with medac concerning Methotrexate Subcutaneous Injection in Japan

Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan.

Original source: https://health.economictimes.indiatimes.com/news/pharma/eisai-enters-into-licensing-agreement-with-medac-concerning-methotrexate-subcutaneous-injection-in-japan/69263812?utm_source=RSS&utm_medium=ETRSS

Also Read:   Glenmark receives orphan drug designation for its antibody candidate for multiple myeloma